Could GLP-1 Obesity Drugs Also Reduce Prostate Cancer Risk? A Case for Clinical Trials | Research

The takeaway

Epidemiologic data suggest GLP-1 receptor agonists may reduce prostate cancer risk, prompting researchers to outline the biological rationale and plan a prospective clinical trial.

Decreased PC risk after GLP-1 RA initiation
Epidemiologic data suggest prostate cancer risk may decrease following initiation of GLP-1 receptor agonist therapy, though prospective trial confirmation is needed

What the researchers found

This narrative review synthesizes epidemiologic evidence suggesting that GLP-1 receptor agonist use may be associated with decreased prostate cancer risk. The authors examine how lifestyle interventions affect men with prostate cancer, the relationship between GLP-1 RA use and prostate cancer risk, and potential mechanisms of action on tumor biology. The review provides the rationale for a planned prospective clinical trial evaluating GLP-1 RA effects on prostate cancer.

Why it matters

Prostate cancer is the most common cancer in men, and obesity is a known risk factor for aggressive disease. If GLP-1 receptor agonists — already widely prescribed for diabetes and obesity — also reduce prostate cancer risk or progression, it could represent an important secondary benefit for millions of men already taking these peptide drugs.

How the study worked

Narrative review of epidemiologic data on GLP-1 receptor agonist use and prostate cancer risk, combined with mechanistic exploration of how these peptide drugs could affect tumor biology. The review also defines metabolic changes in men with prostate cancer following lifestyle intervention and provides rationale for a prospective clinical trial.

Who was studied

Review focusing on men with localized prostate cancer

What this study cannot tell us

This is a narrative review presenting a rationale for future research, not a systematic review or meta-analysis. The epidemiologic association between GLP-1 RA use and reduced prostate cancer risk is observational and subject to confounding. No clinical trial results are reported — the trial is planned but not yet completed.

How to read the evidence

This is a preliminary-grade narrative review. While it synthesizes compelling epidemiologic signals and biological rationale, no prospective clinical trial data exist yet. The planned trial will be critical for establishing a causal relationship.

When this study was published

Published in 2025, this is very timely given the explosive growth of GLP-1 RA prescribing and increasing interest in their extra-metabolic effects.

The bigger picture

GLP-1 receptor agonists continue to find potential applications far beyond diabetes — cardiovascular protection, kidney disease, fatty liver, Alzheimer's, and now potentially cancer prevention. If confirmed, an anti-cancer effect would add significant value to the risk-benefit profile of these peptide drugs, particularly for obese men who are already at elevated prostate cancer risk.

Questions still open

Is the reduced prostate cancer risk from GLP-1 RAs directly due to the peptide's effects on tumor biology, or indirectly through weight loss and metabolic improvement?
Which specific molecular pathways might GLP-1 receptor activation modulate in prostate cancer cells?
Would GLP-1 RAs be more effective at preventing prostate cancer or slowing progression of existing localized disease?

Common questions

Could taking Ozempic or similar drugs help prevent prostate cancer?

Early epidemiologic data suggest men who start GLP-1 receptor agonists may have lower prostate cancer risk, but this hasn't been proven in a clinical trial yet. The association could be due to the drugs' effects on obesity and metabolism rather than a direct anti-cancer effect. A prospective trial is being planned to investigate this properly.

How might GLP-1 drugs affect prostate cancer biology?

The review explores several potential mechanisms: GLP-1 RAs reduce obesity (a risk factor for aggressive prostate cancer), lower insulin levels (insulin can promote cancer cell growth), reduce inflammation, and may have direct effects on tumor biology. The exact mechanisms need to be confirmed through the planned clinical trial.

Read the original research

GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials.

Urology, 201, 152-158

View on PubMed ↗Publisher’s paper ↗

Citation

Fang, Andrew; Frigo, Daniel E; Hahn, Andrew; Razouki, Zayd; Hwang, Jessica; Koutroumpakis, Efstratios; Lawen, Tarek; Smith, Matthew; Hamilton-Reeves, Jill; DiGiovanni, John; Higgason, Noel; Garcia, Rebekka S; Chapin, Brian F; Pettaway, Curtis; Chery, Lisly; Troncoso, Patricia; Logothetis, Christopher; Daniel, Carrie R; Wei, Peng; Gregg, Justin R. (2025). GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials.. Urology, 201, 152-158. https://doi.org/10.1016/j.urology.2025.04.056